Matthew Lee

Matthew Lee is an associate in Goodwin’s Technology and Life Sciences group in London, focusing on transactions in the life sciences, healthcare and technology sectors. Matt advises growth companies and investors on a broad range of corporate matters with a particular focus on venture capital financings, capital markets transactions, M&A, corporate reorganisations, and general corporate matters. Matt advises clients through every stage of the corporate life cycle.

In 2024, Matt spent six months seconded to the legal team at Kinnevik in London, a leading growth investment fund. As part of the secondment, Matt supported Kinnevik’s portfolio companies, advising on new and follow-on investments, exits, and Kinnevik’s fund investments.

Prior to joining Goodwin in 2020, Matt was an associate in the Corporate Finance and M&A Department at Bryan Cave Leighton Paisner LLP.

Matt’s representative experience includes:

Venture Capital Financings – Investor

• Jeito Capital on their co-led $156 million oversubscribed Series B financing round in Quell Therapeutics, the world leader in the development of engineered T-regulatory cell therapies for serious medical conditions driven by the immune system.
• Kinnevik on its lead $41 million investment into a $110 million funding round in Mews and its subsequent investment as part of Mews’ $75 million convertible loan note funding round led by Tiger Global in 2025. 
• The investment syndicate on a c. $120 million Series A funding into an early-stage biotechnology company based in the Netherlands. 
• Oxford Science Enterprises on its seed investments into Archangel Lightworks, Ground Truth Labs and others. 
• Anthos Capital and Bessemer Ventures on their investment into Good Job Games as part of their $60 million financing round. 
• Eka Ventures on multiple investments, including its early-stage investments into Hesta Health, Ditto Daily, and others. 
• Lightspeed Ventures on its Series A and Series B investments in Lightyear.
• Stride Capital on multiple early-stage investments.

Venture Capital Financings – Company

• Artificial Labs, a provider of digital broking and underwriting technology, on its $45 million Series B. 
• Tenpoint Therapeutics on its $235 million Series B and credit facility financing. Tenpoint is a global biotechnology company focused on the commercialization of YUVEZZI™, the first and only dual-agent eye drop for the treatment of presbyopia.
• Acorai, a cardiac monitoring device company, on its $4.5 million oversubscribed series seed financing round led by Solardis Health Ventures.
• Quanta Dialysis Technologies, a portable dialysis device company, on multiple private funding rounds, including its $245 million oversubscribed Series D funding round and its most recent $60 million Series E funding round.
• Achilles Therapeutics, a clinical-stage biopharmaceutical company developing personalised T cell therapies, on the completion of its £52.7 million Series C. 
• Adcendo, a clinical-stage biotechnology company developing breakthrough antibody-drug conjugates, on the closing of an oversubscribed $135 million Series B financing round. 
• Rockend Limited, a biotechnology company aiming to create novel cell therapeutics, on its seed financing and subsequent seed extension financing.
• Wintermute Trading Limited, a leading global crypto market maker, on their $2.8 million Series A funding round and subsequent $20 million Series B funding round.

Capital Markets

• COMPASS Pathways plc on its 2020 $146.6 million NASDAQ IPO and multiple follow-on financings, including its $144 million follow-on offering in 2021, its senior secured term loan facility of up to $50 million with Hercules Capital, Inc., and up to $285 million private placement financing led by healthcare specialist investors TCGX and Aisling Capital in 2023, and its c. $150 million public offering in 2026. COMPASS is a mental healthcare company dedicated to accelerating patient access to evidence-based innovation in mental health.
• Centessa Pharmaceuticals on its $379.5 million IPO on Nasdaq.
• Achilles Therapeutics on its $175.5 million IPO on Nasdaq.

M&A

• Pulsic, a leading provider of electronic design automation software, on its acquisition by Cadence. 
• A co-working office space provider on its insolvent sale to an investment syndicate. 
• A biotechnology company on its entry into an option to acquire agreement with a global pharmaceutical company. 
• Multiple corporate real estate transactions acting for both buyers and sellers in connection with the sale of logistics and office-based real estate.*
• Acting for the buyer on the purchase of a London-based post-production company.*
• Acting for the buyer on the purchase of a Dubai-incorporated holiday rental management company by a property management platform.*

*Denotes experience prior to joining Goodwin.